Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
Thrombosis occurs in 37% of children with acute lymphoblastic leukaemia (ALL) and is related to an L-asparaginase-induced acquired antithrombin (AT) deficiency. The incidence dictates the need for anticoagulant prophylaxis. Direct thrombin inhibitors (DTI) are independent of AT for effect and may thus have advantages in this population. The objective of this study was to determine the interaction of an AT deficiency with the anticoagulant effects of a DTI and a low molecular weight heparin (LMWH). Plasma samples from children with ALL were pooled (mean AT 0.53 U/ml). LMWH 0.3 and 0.7 U/ml or melagatran 0.3 and 0.5 micromol/l were added to the pools, then divided and AT was added back to one aliquot. In additional experiments, AT was added to AT immuno-depleted plasma. Endogenous thrombin generation capacity (ETGC) was assessed by the continuous method. In plasma with LMWH, there was a 66-88% decrease in ETGC in AT-normalised samples compared with neat. Conversely, no significant difference in ETGC with or without AT added for melagatran was seen. Experiments with AT-depleted plasma showed no effect of AT level on anticoagulant activity of DTI, but a significant relationship for LMWH. By contrast to LMWH, DTI provides a consistent anticoagulant response independent of AT levels in children with AT deficiency.
Kuhle
Stefan
S
Pediatric Thrombosis Program, Stollery Children's Hospital, Edmonton, AB, Canada.
Lau
Alice
A
Bajzar
Laszlo
L
Vegh
Patsy
P
Halton
Jacqueline
J
Cherrick
Irene
I
Anderson
Ron
R
Desai
Sunil
S
McCusker
Patricia
P
Wu
John
J
Abshire
Thomas
T
Mahoney
Donald
D
Mitchell
Lesley
L
D000293:Adolescent; D020152:Antithrombin III Deficiency / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D000991:Antithrombins / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D016014:Linear Models; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D013917:Thrombin / Q000378:metabolism
D000991:Antithrombins; D001384:Azetidines; D001596:Benzylamines; D006495:Heparin, Low-Molecular-Weight; C109573:melagatran; D013917:Thrombin; D001215:Asparaginase